Conclusions FOLFOX4 chemotherapy is likely to be a cost-effective option compared with sorafenib in the treatment of advanced hepatocellular carcinoma in ChinaPengfei ZhangFeng WenQiu LiDigestive and Liver DiseaseZhang P, Wen F, Li Q. FOLFOX4 or sorafenib as the first- line treatments for ...
Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis. Int J Radiat Oncol Biol Phys. 2017;99(2):417-426. doi:...
AIM:To compare XELOX and FOLFOX4 as colon cancer adjuvant chemotherapy based on MOSAIC and No.16968 trails from Chinese cost-effectiveness perspective.METHODS:A decision-analytic Markov model was developed to compare the FOLFOX4 and XELOX regimens based MOSAIC and No.16968 trial.Five states were in...
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. METHODS...
The treatments compared were nivolumab, ipilimumab and nivolumab, trifluridine and tipiracil (third‐line treatment), and mFOLFOX6 and cetuximab (first‐line treatment). Disease progression, drug toxicity, and survival rates were based on the CheckMate 142, study of TAS‐102 in patients with ...
Objective: The first aim was to describe the usage patterns of treatments (chemotherapy and targeted biologics) and treatment sequences administered to mCRC patients and the factors associated with the receipt of common treatment sequences. The common treatment sequences of interest were: 1) first-...
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysisChemotherapyHepatocellular carcinomaPharmaco-economicSorafenibBackground: This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular ...
AIM:To compare XELOX and FOLFOX4 as colon cancer adjuvant chemotherapy based on MOSAIC and No.16968 trails from Chinese cost-effectiveness perspective.METHODS:A decision-analytic Markov model was developed to compare the FOLFOX4 and XELOX regimens based MOSAIC and No.16968 trial.Five states were ...
The CMA estimated the costs of RAS testing, premedication, drug acquisition, treating infusion reactions (IRs), supportive therapy, and biweekly administration of chemotherapy, cetuximab (500mg/m2), and panitumumab (6mg/kg) over 43weeks (median progression-free survival). To calculate dose and ...
Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Harvey RD, El-Rayes BF, Flowers CR (2014) Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 13:219–225...